Compile Data Set for Download or QSAR
maximum 50k data
Found 368 with Last Name = 'lachal' and Initial = 'j'
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212110(US9290485, 142)
Affinity DataIC50:  0.0224nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212116(US9290485, 148)
Affinity DataIC50:  0.0300nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212114(US9290485, 146)
Affinity DataIC50:  0.0400nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM211977(US9290485, 9)
Affinity DataIC50:  0.0912nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212136(US9290485, 168)
Affinity DataIC50:  0.100nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212115(US9290485, 147)
Affinity DataIC50:  0.100nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212004(US9290485, 36)
Affinity DataIC50:  0.134nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM211974(US9290485, 6)
Affinity DataIC50:  0.200nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212113(US9290485, 145)
Affinity DataIC50:  0.200nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212134(US9290485, 166)
Affinity DataIC50:  0.200nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212135(US9290485, 167)
Affinity DataIC50:  0.200nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212141(US9290485, 173)
Affinity DataIC50:  0.400nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542738(CHEMBL4637027)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542741(CHEMBL4647950)
Affinity DataIC50: <0.700nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542731(CHEMBL4642845)
Affinity DataIC50: <0.700nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212124(US9290485, 156)
Affinity DataIC50:  0.920nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50542731(CHEMBL4642845)
Affinity DataIC50:  1nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50542738(CHEMBL4637027)
Affinity DataIC50:  1nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212109(US9290485, 141)
Affinity DataIC50:  1.20nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50542724(CHEMBL4636415)
Affinity DataIC50:  2nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
In DepthDetails ArticlePubMed
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542740(CHEMBL4646398)
Affinity DataIC50:  2nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50542740(CHEMBL4646398)
Affinity DataIC50:  2nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212125(US9290485, 157)
Affinity DataIC50:  2nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212122(US9290485, 154)
Affinity DataIC50:  2nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212062(US9290485, 94)
Affinity DataIC50:  2.10nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212111(US9290485, 143)
Affinity DataIC50:  2.60nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542728(CHEMBL4635912)
Affinity DataIC50:  3nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542733(CHEMBL4646141)
Affinity DataIC50:  3nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50542723(CHEMBL4643449)
Affinity DataIC50:  3nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212123(US9290485, 155)
Affinity DataIC50:  3nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212137(US9290485, 169)
Affinity DataIC50:  3nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542723(CHEMBL4643449)
Affinity DataIC50:  3nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212043(US9290485, 75)
Affinity DataIC50:  3.10nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212083(US9290485, 115)
Affinity DataIC50:  3.30nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542724(CHEMBL4636415)
Affinity DataIC50:  4nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542725(CHEMBL4637683)
Affinity DataIC50:  4nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50542730(CHEMBL4647909)
Affinity DataIC50:  4nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212129(US9290485, 161)
Affinity DataIC50:  4nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212120(US9290485, 152)
Affinity DataIC50:  4nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212126(US9290485, 158)
Affinity DataIC50:  4nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212108(US9290485, 140)
Affinity DataIC50:  4.60nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212107(US9290485, 139)
Affinity DataIC50:  4.90nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212131(US9290485, 163)
Affinity DataIC50:  5nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212130(US9290485, 162)
Affinity DataIC50:  5nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50542725(CHEMBL4637683)
Affinity DataIC50:  6nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542730(CHEMBL4647909)
Affinity DataIC50:  6nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212133(US9290485, 165)
Affinity DataIC50:  6nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212057(US9290485, 89)
Affinity DataIC50:  6nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542735(CHEMBL4635286)
Affinity DataIC50:  6nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50542728(CHEMBL4635912)
Affinity DataIC50:  7nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 368 total ) | Next | Last >>
Jump to: